Home » Stocks » INSM

Insmed, Inc. (INSM)

Stock Price: $32.30 USD 0.05 (0.16%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 3.34B
Revenue (ttm) 164.41M
Net Income (ttm) -294.09M
Shares Out 97.61M
EPS (ttm) -3.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $32.30
Previous Close $32.25
Change ($) 0.05
Change (%) 0.16%
Day's Open 31.95
Day's Range 31.39 - 32.47
Day's Volume 473,827
52-Week Range 18.58 - 45.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BRIDGEWATER, N.J., April 7, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

1 week ago - PRNewsWire

BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

4 weeks ago - PRNewsWire

BRIDGEWATER, N.J., March 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

1 month ago - PRNewsWire

BRIDGEWATER, N.J., Feb. 25, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

1 month ago - PRNewsWire

Insmed Incorporated (NASDAQ: INSM) has announced topline results from the Phase 1 study evaluating treprostinil palmitil inhalation powder (TPIP) in healthy volunteers. The company plans to present comp...

2 months ago - Benzinga

BRIDGEWATER, N.J., Feb. 19, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

2 months ago - PRNewsWire

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BRIDGEWATER, N.J., Feb. 16, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

2 months ago - PRNewsWire

BRIDGEWATER, N.J., Feb. 12, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

2 months ago - PRNewsWire

BRIDGEWATER, N.J., Feb. 5, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

2 months ago - PRNewsWire

BRIDGEWATER, N.J., Dec. 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

4 months ago - PRNewsWire

Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.

4 months ago - Zacks Investment Research

BRIDGEWATER, N.J., Nov. 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

4 months ago - PRNewsWire

BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

5 months ago - PRNewsWire

BRIDGEWATER, N.J., Nov. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

5 months ago - PRNewsWire

Insmed Incorporated (INSM) CEO Will Lewis on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Insmed (INSM) delivered earnings and revenue surprises of -6.78% and -6.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

BRIDGEWATER, N.J., Oct. 29, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

5 months ago - PRNewsWire

BRIDGEWATER, N.J., Oct. 28, 2020 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

5 months ago - PRNewsWire

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

6 months ago - PRNewsWire

Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.

Other stocks mentioned: ALXN, AMGN, BMRN, REGN, UTHR, VRTX
6 months ago - 24/7 Wall Street

BRIDGEWATER, N.J., Sept. 9, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

7 months ago - PRNewsWire

BRIDGEWATER, N.J., Sept. 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

7 months ago - PRNewsWire

On Friday, Insmed (INSM) hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 83, up from 79 the day before.

7 months ago - Investors Business Daily

Insmed Incorporated (INSM) CEO William Lewis on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Insmed (INSM) delivered earnings and revenue surprises of -10.34% and 16.58%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

BRIDGEWATER, N.J., Aug. 6, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

8 months ago - PRNewsWire

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

BRIDGEWATER, N.J., July 27, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

8 months ago - PRNewsWire

BRIDGEWATER, N.J., July 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, to...

8 months ago - PRNewsWire

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

9 months ago - PRNewsWire

BRIDGEWATER, N.J., June 24, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, tod...

9 months ago - PRNewsWire

BRIDGEWATER, N.J., June 8, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, toda...

10 months ago - PRNewsWire

Insmed Incorporated (INSM) CEO Will Lewis on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Insmed (INSM) delivered earnings and revenue surprises of -10.45% and 9.20%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Insmed (NASDAQ:INSM) were unchanged at $21.05 after the company reported Q1 results.

11 months ago - Benzinga

Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

Insmed, Incorporated (INSM) CEO Will Lewis on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Insmed (INSM) delivered earnings and revenue surprises of -1.72% and 0.19%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares jump in response to a pair of analyst upgrades.

1 year ago - The Motley Fool

Shares soar after Insmed reports upbeat clinical news.

1 year ago - The Motley Fool

Insmed Inc. (NASDAQ: INSM) is one of the few biotechs not tied to the coronavirus that is making a big move to start out the week.

1 year ago - 24/7 Wall Street

Insmed stock rocketed Monday after the biotech company said its non-cystic fibrosis bronchiectasis treatment showed promise in a Phase 2 study. Patients experienced fewer exacerbations.

1 year ago - Investors Business Daily

Shares of Insmed Inc. INSM, -1.11% rocketed 51% toward a nine-month high in premarket trading Monday, after the biopharmaceutical company said a phase 2 trial of its treatment of non-cystic fibrosis bro...

1 year ago - Market Watch

When searching for massive gains that can be achieved in the blink of an eye, look no further than healthcare stocks. Here are seven that stand out according to the Street.

Other stocks mentioned: ATEC, BDSI, BTAI, FOLD, GERN, INO
1 year ago - InvestorPlace

Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

Insmed, Inc. (INSM) CEO Will Lewis on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a tr... [Read more...]

Industry
Biotechnology
IPO Date
Jun 1, 2000
CEO
William Lewis
Employees
521
Stock Exchange
NASDAQ
Ticker Symbol
INSM
Full Company Profile

Financial Performance

In 2020, Insmed's revenue was $164.41 million, an increase of 20.48% compared to the previous year's $136.47 million. Losses were -$294.09 million, 15.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Insmed stock is "Strong Buy." The 12-month stock price forecast is 53.56, which is an increase of 65.82% from the latest price.

Price Target
$53.56
(65.82% upside)
Analyst Consensus: Strong Buy